Barinthus Biotherapeutics

BRNS | NASDAQ

Price Alert Chart Builder DCF Calculator

$0.74

-$0.02 (-2.50%)

At close: Sep 8, 2026, 4:00 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-2.50%

(1D)

Rating

Updated: Aug 27, 2026

13.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $30.23M

1D Range

0.66 0.76

52W Range

0.51 1.83

Valuation (TTM)

PE -0.72

PB 0.53

EV/EBITDA 0.50

Valuation (NTM)

Forward PE N/A

Forward PEG -0.04

Price Target $3

Cash Flow

FCF Yield -87.4%

SBC Adj. FCF Yield -91.6%

SBC Impact -4.8%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y 0.0% | -51.8%

Dil EPS 3Y | 5Y 21.1% | -27.7%

FCF 3Y | 5Y 35.7% | -1.7%

Returns

ROA -51.0%

ROE -59.2%

ROIC -61.1%

Financial Health

Net Cash

$59.3M

Current Ratio 5.54

Interest Coverage -842.20

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company...

Sector Healthcare

Industry Biotechnology

Employees 14

IPO Date Apr 29, 2021

Website www.barinthusbio.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 6, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+305.41%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞